TR201908660T4 - TRIGGER OF CANCER CELLS WITH LOW-DOSE NALTREXONE. - Google Patents

TRIGGER OF CANCER CELLS WITH LOW-DOSE NALTREXONE. Download PDF

Info

Publication number
TR201908660T4
TR201908660T4 TR2019/08660T TR201908660T TR201908660T4 TR 201908660 T4 TR201908660 T4 TR 201908660T4 TR 2019/08660 T TR2019/08660 T TR 2019/08660T TR 201908660 T TR201908660 T TR 201908660T TR 201908660 T4 TR201908660 T4 TR 201908660T4
Authority
TR
Turkey
Prior art keywords
naltrexone
subject
phase
rna
administered
Prior art date
Application number
TR2019/08660T
Other languages
English (en)
Turkish (tr)
Inventor
Dalgleish Angus
Liu Wai
Original Assignee
Cancer Vaccine Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Vaccine Inst filed Critical Cancer Vaccine Inst
Publication of TR201908660T4 publication Critical patent/TR201908660T4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2019/08660T 2014-06-09 2015-06-09 TRIGGER OF CANCER CELLS WITH LOW-DOSE NALTREXONE. TR201908660T4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1410216.4A GB201410216D0 (en) 2014-06-09 2014-06-09 Therapeutic

Publications (1)

Publication Number Publication Date
TR201908660T4 true TR201908660T4 (en) 2019-07-22

Family

ID=51266919

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08660T TR201908660T4 (en) 2014-06-09 2015-06-09 TRIGGER OF CANCER CELLS WITH LOW-DOSE NALTREXONE.

Country Status (10)

Country Link
US (3) US11065245B2 (enExample)
EP (1) EP3151831B1 (enExample)
JP (1) JP6620338B2 (enExample)
DK (1) DK3151831T3 (enExample)
ES (1) ES2730348T3 (enExample)
GB (1) GB201410216D0 (enExample)
PL (1) PL3151831T3 (enExample)
PT (1) PT3151831T (enExample)
TR (1) TR201908660T4 (enExample)
WO (1) WO2015189597A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases
GB201704909D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
GB201704913D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Method
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
WO2020178447A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method for determining efficacy
EP3934648A1 (en) * 2019-03-06 2022-01-12 LDN Pharma Limited Method of monitoring treatment
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
WO2021011529A1 (en) 2019-07-15 2021-01-21 Rovaxa Opioid growth factor receptor (ogfr) antagonists, in particular naloxone and/or naltrexone for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
JP5647098B2 (ja) * 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic

Also Published As

Publication number Publication date
US20210308125A1 (en) 2021-10-07
US12144807B2 (en) 2024-11-19
US20170119755A1 (en) 2017-05-04
US20250032481A1 (en) 2025-01-30
JP2017519006A (ja) 2017-07-13
ES2730348T3 (es) 2019-11-11
DK3151831T3 (da) 2019-06-24
PT3151831T (pt) 2019-06-18
EP3151831B1 (en) 2019-03-13
WO2015189597A1 (en) 2015-12-17
EP3151831A1 (en) 2017-04-12
US11065245B2 (en) 2021-07-20
PL3151831T3 (pl) 2021-05-31
JP6620338B2 (ja) 2019-12-18
GB201410216D0 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
TR201908660T4 (en) TRIGGER OF CANCER CELLS WITH LOW-DOSE NALTREXONE.
Faraco et al. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo
Lutay et al. Bacterial control of host gene expression through RNA polymerase II
NZ712823A (en) Molecular diagnostic test for cancer
BR112017024331A2 (pt) composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
EP3064220A3 (en) Compositions and methods for the treatment of infections and tumors
BR112021024463A2 (pt) Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas
ITMI20021527A1 (it) Anticorpi anti componente c5 del complemento e loro uso
Stefanaki et al. Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study
EP4365300A3 (en) Treatment/prevention of disease by linc complex inhibition
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
PH12022550846A1 (en) Thienopyrimidones as trpa1 inhibitors
Davis et al. The opioid antagonist, β-funaltrexamine, inhibits chemokine expression in human astroglial cells
Sardoiwala et al. Melatonin mediated inhibition of EZH2-NOS2 crosstalk attenuates inflammatory bowel disease in preclinical in vitro and in vivo models
Wang et al. Dexmedetomidine mitigates neuroinflammation and improves early postoperative neurocognitive dysfunction in rats by enhancing autophagy
WO2017087947A3 (en) Method of treatment of follicular lymphoma with a btk inhibitor
MX2022004571A (es) Alquilésteres de alfa-metil-dl-tirosina para uso en el tratamiento de cáncer.
Polytarchou et al. X-rays affect the expression of genes involved in angiogenesis
MX2022005900A (es) Agentes antisentido de il-34 y metodos de uso de los mismos.
Mauro Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia
WO2016145362A3 (en) Inhibitors of dek protein and related methods
Yu et al. Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression
EA202192330A1 (ru) Олигонуклеотиды, препятствующие экспрессии белка, ассоциированного с синдромом ломкой х-хромосомы, и способы их применения
Kuo et al. Characterization of quinolone-resistant Enterococcus faecalis isolates from healthy chickens and pigs in Taiwan
Terai et al. Clinical features of partial atrophic tongue associated with Candida